Diurnal is pleased to report that the first patient has been enrolled into the CATCH (Chronocort As Treatment for Congenital adrenal Hyperplasia) trial. The CATCH trial is a Phase 2 study in patients suffering from Congenital Adrenal Hyperplasia and is being run by the National Institute of Health (NIH), Maryland, US under a Cooperative Research and Development Agreement (CRADA). The title of the CRADA is "Age-Appropriate Hydrocortisone Formulations for the Treatment of Adrenal Insufficiency including Congenital Adrenal Hyperplasia" and the research aims to investigate the use of Chronocort® (circadian hydrocortisone) in patients who suffer from these rare (orphan) diseases.
Martin Whitaker, Chief Executive Officer, Diurnal, stated:
"We are delighted that the CATCH trial has started at the National Institute of Health. This is a significant milestone for Diurnal. The CATCH trial will demonstrate the efficacy of Chronocort in patients for the first time"
For further information please contact:
Martin Whitaker, PhD (Chief Executive Officer)
+44 (0) 871 716 8848